[Clinical trials of prophylaxis of toxoplasmic retinochoroiditis recurrences by immunotherapy using B.C.G. (author's transl)].
7 patients affected by recurrent retinochoroiditis certainly or probably due to toxoplasma Gondii underwent immunotherapy by B.C.G. The follow-up after immunotherapy varied from 14 months to 50 months with an average of 28 months. 5 out of the 7 patients (71%) had recurrences of the retinochoroiditis 2 months to 3 years after the treatment. Even though the series is small, the results are so discouraging that we do not recommend to go further with this technique. At present we try other forms of immunotherapy. Assessment of their value will require a 5 years follow-up.
D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use*; D002825:Chorioretinitis / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D014126:Toxoplasmosis, Ocular / Q000517:prevention & control*
D001500:BCG Vaccine
Essai de prophylaxis des récidives de rétinochoroïdite toxoplasmique par immunothérapie au B.C.G.